Owen Mumford Publishes Annual Responsible Action Report

Highlighting B Corp Certification and Science-Based Targets Milestones

Owen Mumford (medical device manufactuer) has published its latest annual Responsible Action Report, highlighting progress and achievements in 2021 including its recent B Corp certification and alignment with the Science Based Targets initiative (SBTi) to achieve net zero carbon emissions by 2045, as the company continues to strengthen its sustainability strategy and future-proof its operations.

In June 2021, Owen Mumford was awarded B Corp certification in recognition of its commitment to corporate social responsibility regarding the environment, governance, community engagement, employee support, and customer stewardship. The certification makes Owen Mumford one of the first medical device manufacturers in the world to achieve this, joining over 4,000 global businesses working towards improving their benchmarks and raising standards across all industries.

Sustainability continues to be a key area of focus for Owen Mumford, demonstrated through commitments towards emissions reduction targets with the SBTi. The company has set a target to reach a 50% reduction in carbon emissions by 2030 and become net zero by 2045. Owen Mumford has also joined the Race to Zero movement in 2021, a collaboration of leading companies across the globe supporting efforts to achieve zero carbon recovery.

The report charts the organization’s progress against its chosen United Nations Sustainable Development Goals (SDGs), covering a variety of well-being, infrastructural, and responsible consumption themes. Highlights for 2021 include continued support for the promotion of women in STEM subjects through local collaboration with schools and colleges, to continued evaluation of its logistics output to reduce carbon emissions and lead times to customers. Other initiatives support the company’s commitment to its associates, customers, products, and the planet.

“This past year has been challenging for us all as we entered the second year of the pandemic. Thankfully, 2021 marked a year of growth, action and above all else, resilience for Owen Mumford. Whether achieving B Corp certification, committing to reducing our emissions footprint, or continuing investment in more sustainable products, we have a great deal to be proud of,” said Jarl Severn, CEO of Owen Mumford.

He concluded, “Our goal is to continue with a positive influence on the medical device industry, leading by example on how products should be responsibly made, companies should be ethically run, and futures should be protected. I hope that the hard work and commitment from everyone at Owen Mumford encourages other companies and individuals to implement their own action plans and work towards a better future for everyone.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”